- There is a great need for a reliable way to diagnose ovarian cancer, especially in the early stages.
- Analysis of markers in blood offers many advantages in terms of cost and ease of sampling.
- Researchers at Moffitt Cancer Center have identified a panel of 21 proteins from patient plasma that correlate with ovarian cancer.
FEATURES AND BENEFITS
- The 21 proteins are differentially expressed in plasma, affording easy sampling from the patient.
- The panel is based on a large sample size of 160 women, improving reliability of the results.
- Eight of the proteins are differentially expressed in early stage ovarian cancer, where there is a great need for a reliable test.
- The protein panel offers promise as a clinical test for diagnosis, screening and monitoring therapy in ovarian cancer.
STAGE OF DEVELOPMENT
An assay is being developed for clinical validation studies.
PUBLICATION/PATENT
Patent application pending.
Contact
Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596
06B098
